SINGAPORE and SAN DIEGO – April 14, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a $14 million fundraising round co-led by new investor EDBI together with existing investors Anzu Partners and University of Tokyo Edge Capital Partners (UTEC). EDBI invested through its Special Situation Fund for Startups (SSFS) scheme, which supports promising Singapore startups to sustain their growth momentum amidst the challenging environment and emerge stronger from the COVID-19 pandemic. The new round brings ImmunoScape’s total funding in the past year to $25 million.
ImmunoScape will use the funding to enlarge its Singapore-based team, further its expansion into the U.S., and scale up its newly announced San Diego laboratory. The company will also be able to continue advancing the capabilities of its Deep Immunomics platform that enables the characterization of a patient’s immunome at ultra-high resolution. ImmunoScape will be working to increase its capacity for in-house R&D activities and to expand its partnerships with biopharma and leading academics in drug development efforts within immuno-oncology, infectious disease, and autoimmune disease.
“Since our last funding announcement less a year ago, we have made significant strides in our collaborations with organizations such the NIAID and Johns Hopkins, with whom we published multiple COVID-19 studies, one of which was recently spotlighted by the NIH,” said Choon Peng Ng, CEO of ImmunoScape. “We also established a Scientific Advisory Board chaired by our co-founder, Evan Newell, and grown our U.S. presence with experienced scientists and biotech executives, like Geoff Nosrati, as our Chief Business Officer. This new financing will allow us deepen our relationships with partners in the development of next generation therapeutics.”
ImmunoScape’s Deep Immunomics platform integrates single-cell analysis technologies and cutting-edge bioinformatics for both drug discovery and high-dimensional immune profiling. For example, its TargetScape® technology can be used to detect rare antigen specific T-cells with frequencies as low as 1 in 100,000 CD8+ cells, and simultaneously provide comprehensive phenotypic information for these antigen specific T cells.
“ImmunoScape is a global company with a highly differentiated platform that can change the way lifesaving treatments are developed,” said David Michael, Managing Partner at Anzu Partners. “We are delighted to help bring this technology to biopharma leaders and support drug development in immuno-oncology and infectious disease.”
